GlassScriptPhysician profile
Robert L Mclaurin
NPI 1487694360
$1,541.08
in general payments reported to CMS, 2019-2025
28 companies · $29.52 in 2025
The $29.52 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $327 · 2021: $162 · 2022: $205 · 2024: $40.84 · 2025: $29.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $316.60 | 2019-2022 | |
| Janssen Biotech, INC. | $177.18 | 2019-2024 | Erleada |
| Novartis Pharmaceuticals Corporation | $125.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.27 | 2019-2024 | Krazati |
| Amgen INC. | $92.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.79 | 2019-2021 | |
| Seagen INC. | $71.26 | 2019-2020 | |
| Pfizer INC. | $63.31 | 2019-2020 | |
| Eisai INC. | $58.24 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.39 | 2019 | |
| Gilead Sciences, INC. | $38.63 | 2019-2021 | |
| Daiichi Sankyo INC. | $33.73 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.22 | 2019 | |
| Merck Sharp & Dohme LLC | $29.86 | 2019-2020 | |
| Genzyme Corporation | $27.52 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $23.79 | 2019 | |
| Celgene Corporation | $21.12 | 2019 | |
| Incyte Corporation | $19.57 | 2022 | |
| Dova Pharmaceuticals | $18.76 | 2019 | |
| Abbvie INC. | $18.17 | 2019 | |
| Tesaro, INC. | $17.36 | 2019 | |
| Epizyme, INC. | $15.62 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.57 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.65 | 2019 | |
| Beigene USA, INC. | $13.69 | 2020 | |
| Lilly USA, LLC | $13.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.44 | 2019 | |
| Exelixis INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mclaurin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.